These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8930776)

  • 1. Pharmacokinetics of trapidil in patients with chronic liver disease.
    Berndt A; Looby M; Pönicke K; Zipprich B; Weiss M
    J Clin Pharmacol; 1996 Oct; 36(10):897-902. PubMed ID: 8930776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease.
    Berndt A; Pönicke K; Weiss M
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):492-3. PubMed ID: 1490801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis.
    Harder S; Thürmann PA; Hellstern A; Benjaminov A
    Br J Clin Pharmacol; 1996 Oct; 42(4):443-9. PubMed ID: 8904615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the PDGF-antagonist trapidil in patients with and without renal impairment.
    Thürmann PA; Harder S; Wolter K; Münck AC; Fritschka E
    Clin Nephrol; 1997 Feb; 47(2):99-105. PubMed ID: 9049457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of trapidil tablets.
    Weiss M; Sziegoleit W; Pönicke K; Schobess M; Fahr A; Mest HJ
    Arzneimittelforschung; 1989 Sep; 39(9):1137-8. PubMed ID: 2590264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gas chromatographic evaluation of trapidil and its desethyl metabolite in biological fluids for pharmacokinetic and bioavailability investigations.
    Marzo A; Pasotti V; Maggi GC
    Arzneimittelforschung; 1987 Aug; 37(8):947-50. PubMed ID: 3675691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():25-32. PubMed ID: 10702884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cimetidine clearance and bioavailability in hepatic cirrhosis.
    Sonne J; Poulsen HE; Døssing M; Larsen NE; Andreasen PB
    Clin Pharmacol Ther; 1981 Feb; 29(2):191-7. PubMed ID: 7460483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
    Ohnishi K
    Hepatogastroenterology; 1990 Jul; 37 Suppl 1():6-10. PubMed ID: 2210613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment.
    Siegerstetter V; Huber M; Ochs A; Blum HE; Rössle M
    Hepatology; 1999 Jan; 29(1):33-8. PubMed ID: 9862846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.
    Boike SC; Pue M; Audet PR; Freed MI; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    J Clin Pharmacol; 1994 Dec; 34(12):1199-207. PubMed ID: 7738216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis.
    Hu OY; Tang HS; Chang CL
    J Clin Pharmacol; 1995 Mar; 35(3):250-8. PubMed ID: 7608313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regional liver circulation and scintigraphic imaging of portal circulation with 133Xe].
    Kroiss A
    Acta Med Austriaca Suppl; 1984; 31():1-28. PubMed ID: 6599830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
    Morgan MY; Stambuk D; Cottrell J; Mann SG
    Aliment Pharmacol Ther; 1990 Feb; 4(1):83-96. PubMed ID: 2104076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE; Münch U; Meier J
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trapidil decreases the aggregation of platelets from heart transplant recipients ex vivo.
    Jovin IS; Taborski U; Szalay Z; Friedel A; Segieth I; Jovin A; Heidinger K; Schreiner K; Frass O; Klövekorn WP; Müller-Berghaus G
    Transplant Proc; 2006 Jun; 38(5):1523-5. PubMed ID: 16797349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
    Krakamp B; Tanswell P; Leidig P; Vogel H; Schmitz R; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):71-3. PubMed ID: 2917592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.